Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Altamira Therapeutics Ltd
Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies
22 janv. 2025 09h00 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Exploring use of Altamira’s RNA nanoparticles in conjunction with radiopharmaceutical cancer treatment Project collaboration partner will have...
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
31 déc. 2024 09h00 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Further proof of great versatility of Altamira’s platform for extrahepatic RNA deliveryCircular mRNA significantly increasing protein expression...
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
20 déc. 2024 08h00 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Trading to continue under ticker symbol “CYTOF”No reverse stock split planned Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:...
Altamira Therapeutics Provides Update on Nasdaq Listing
04 oct. 2024 16h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the...
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
27 sept. 2024 09h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with strategic contract...
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
24 sept. 2024 08h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within core activities in RNA delivery, supported by move into new...
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
20 sept. 2024 09h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA...
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
19 sept. 2024 16h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked...
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
17 sept. 2024 17h00 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked...
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
16 sept. 2024 08h30 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing...